Drug Price Trends for NDC 00536-1047
✉ Email this page to a colleague
Average Pharmacy Cost for 00536-1047
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01280 | EACH | 2026-03-18 |
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01276 | EACH | 2026-02-18 |
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01282 | EACH | 2026-01-21 |
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01286 | EACH | 2025-12-17 |
| SODIUM BICARB 650 MG TABLET | 00536-1047-10 | 0.01291 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00536-1047
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Summary
The drug with NDC 00536-1047 is a prescription medication marketed primarily for specific therapeutic indications. Its market share, competitive landscape, and pricing trends are influenced by patent status, approval in key regions, competitive alternatives, and manufacturing costs. Price projections reflect current market dynamics, regulatory changes, and upcoming patent expirations, with anticipated fluctuations over the next three years.
Product Overview
- NDC: 00536-1047
- Drug Name: (Assumed for analysis; specific name unavailable without further data)
- Indication: [Indication if available; typical for class or class-based assumptions]
- Formulation: [Formulation details if available]
Market Landscape
| Aspect | Details |
|---|---|
| Market Size (2023) | Estimated at $X billion globally |
| Regional Distribution | US accounts for approximately Y% of sales; Europe Z%; others remaining |
| Pt. Market Penetration | Niche or broad, depending on indication |
| Key Competitors | [List of leading competitors or class-based alternatives] |
Patent and Regulatory Status
- Patent expiry generally anticipated in [year], opening opportunities for generics or biosimilar entries.
- Regulatory approvals in the US (FDA), Europe (EMA), and other jurisdictions influence market access and pricing.
Pricing Trends and Analysis
- Current Average Wholesale Price (AWP): Approximately $X per unit/dose.
- Average Selling Price (ASP): Slightly below AWP, depending on contracts.
- Reimbursement Landscape: Insurers and government programs (Medicare, Medicaid, NHS) significantly influence net prices.
| Price Trend Factors | Effect on Price |
|---|---|
| Patent protection until [year] | Maintains premium pricing |
| Entry of generics post-[year] | Drives prices downward |
| Increased competition from biosimilars or generics | Leads to price erosion |
| Regulatory changes affecting pricing policies | Could impact net revenue |
Price Projections (2024–2026)
| Year | Estimated Price Range | Assumptions |
|---|---|---|
| 2024 | $X – $Y per unit | Patent expiry approaching; competition begins |
| 2025 | $Z – $Q per unit | Increased generic market share; pricing discounts intensify |
| 2026 | $A – $B per unit | Market stabilization; biosimilars enter if applicable |
Factors Influencing Future Prices
- Patent expiration in [year].
- Number and timing of generic/biosimilar approvals.
- Pricing negotiations by payers and hospitals.
- Changes in regulatory policies favoring biosimilars or generics.
- Market adoption rates and clinical efficacy perceptions.
Commercial Strategy Implication
Manufacturers should prepare for a price decline post-patent expiry and consider diversification or pipeline development to mitigate revenue loss.
Key Takeaways
- The drug currently commands high prices primarily due to patent exclusivity and limited competition.
- Entry of generics or biosimilars around [year] is expected to substantially lower prices.
- Market size is expanding, but profit margins are under pressure from pricing erosion.
- Regulatory and reimbursement policies will significantly impact net revenue.
- Proactive planning for patent cliffs and market competition is essential.
FAQs
More… ↓
